Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Preclinical and initial phase I clinical data demonstrate the potency, kinome selectivity, efficacy, and brain penetration of enozertinib in NSCLC with EGFR exon 20 insertions and atypical mutations, warranting further clinical development.
Authors
- F. Anthony Romero (ORCID: https://orcid.org/0000-0001-7917-1459)
- Claire E. Repellin (ORCID: https://orcid.org/0000-0002-6552-3318)
- Chudi Ndubaku (ORCID: https://orcid.org/0000-0003-4183-0417)
- Jason E. Long (ORCID: https://orcid.org/0000-0002-8229-0341)
- Sumeet Salaniwal (ORCID: https://orcid.org/0009-0002-4744-5317)
- Jae Hoon Chang (ORCID: https://orcid.org/0000-0003-3457-7695)
- Edna Chow Maneval (ORCID: https://orcid.org/0000-0001-8131-755X)
- Rupal Patel (ORCID: https://orcid.org/0009-0005-5978-2179)
- Anneleen Daemen (ORCID: https://orcid.org/0000-0001-6287-7105)
- Youngyi Lee (ORCID: https://orcid.org/0000-0003-2293-1634)
- Stephanie W. Ni (ORCID: https://orcid.org/0000-0002-8821-7786)
- Brian R. Blank (ORCID: https://orcid.org/0009-0003-4763-9856)
- Melissa R. Junttila (ORCID: https://orcid.org/0000-0003-3538-1192)
- Pratik S. Multani (ORCID: https://orcid.org/0000-0001-8358-3560)
- Haelee Kim (ORCID: https://orcid.org/0000-0003-0569-7129)
- Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
- Robert Warne (ORCID: https://orcid.org/0009-0009-2738-3121)
- Brenda Chan (ORCID: https://orcid.org/0009-0004-8471-6723)
- Joeng-Woong Baik (ORCID: https://orcid.org/0009-0009-6901-8632)
- Arundhati Das (ORCID: https://orcid.org/0009-0007-3193-3304)
- Chung Ryul Jung (ORCID: https://orcid.org/0000-0001-7969-5885)
- Liliana Soroceanu (ORCID: https://orcid.org/0000-0002-4811-5099)
- Lidia Sambucetti (ORCID: https://orcid.org/0000-0001-9686-5444)
- Younho Lee (ORCID: https://orcid.org/0000-0002-4235-1269)
- Lori S. Friedman (ORCID: https://orcid.org/0000-0001-9127-9892)
- Jessica D. Sun (ORCID: https://orcid.org/0000-0002-9844-9767)
- Ana Maria Ferreira Peixoto Pereira (ORCID: https://orcid.org/0000-0003-4871-0856)
- Padmini Narayanan (ORCID: https://orcid.org/0000-0003-0163-9087)
- Kyung Ah Seo (ORCID: https://orcid.org/0009-0009-4838-8992)
- Gina Andreatta (ORCID: https://orcid.org/0009-0008-6211-7577)
- Matt Panuwat (ORCID: https://orcid.org/0009-0002-6841-0236)
Institutions
- Incheon National University (KR)
- Baylor College of Medicine (US)
- Ligand Pharmaceuticals (United States) (US)
- Virginia Cancer Specialists (US)
- Orchid Pharma (India) (IN)
- Paraza Pharma (Canada) (CA)
- Incheon Medical Center (KR)
- Sunesis (United States) (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1158/0008-5472.can-25-3502
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52